Chondroitin for Skin Aging
Verdict: Insufficient Evidence
Across 3 PubMed studies, the evidence for Chondroitin in Skin Aging grades Tier U — unverified / insufficient. Research is still too limited to draw a firm conclusion.
U ⚫ U Unverified Insufficient Evidence
Why this grade7-layer evidence engine
⚖️
Scoring transparency
All scores computed by a 7-layer evidence engine — fully auditableRaw score 0.41
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
U · Insufficient Evidence
Confidence
71%
Broadly consistent
Evidence level
E3
Single high-quality meta-analysis
▸View the full decision path (audit trail)
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.406
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 無高階證據可裁決
- tier_strict_requirement_check — Tier 條件達標，未降階
- detect_disputes — 偵測到 0 個 hard + 1 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status
PubMed studies (3)L2 · primary research & systematic reviews
Daily oral supplementation with collagen peptides combined with vitamins and other bioactive compounds improves skin elasti
Finding: Skin elasticity improved +40% vs placebo (p<0.0001); histology showed reduced solar elastosis — but chondroitin cannot be isolated as the active agent in this multi-ingredient formula.
View on PubMed Potential anti-ageing effect of chondroitin sulphate through skin regeneration
Finding: CS increased keratinocyte and fibroblast proliferation, stimulated type I procollagen synthesis via ERK pathway, and promoted wound healing in aged skin — in vitro and animal models only, not human RCT.
View on PubMed Drug Screening Implicates Chondroitin Sulfate as a Potential Longevity Pill
Finding: Narrative review concludes CS has favourable pharmacokinetics and tolerability, references RCT efficacy in joint disease — does not present original RCT data for skin aging outcomes.
View on PubMed Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …
L4a US FDA
Cautious
FDA has no questions regarding Gnosis S.P.A.'s conclusion that chondroitin sulfate sodium is generally recognized as safe under its intended conditions of use. source↗
L4b EU EFSA
Against
L4c UK NHS
Against
GPs no longer prescribe chondroitin and glucosamine on the NHS because there's no strong evidence that they are effective as a treatment. NICE recommends that they should not routinely be offered on the NHS. source↗
L4d TW TFDA / 衛福部
Neutral
軟骨素在我國以及美國都不能取得藥品使用許可，祇能當作保健食品來販售。目前並沒有嚴謹的臨床試驗，可以證實軟骨素用於治療膝關節炎的療效。 source↗
L5a NIH Office of Dietary Supplements
Cautious